Skip to content
APAC Capital Brief
Directory

Institution record

CXM

Risk level not supplied1 of 1 licences marked regulated
Source score
6.1
Warnings
0
Comments
0

Licence records

Licences within our coverage (institutions licensed across asia-pacific and the middle east) are listed first. Check each one on the regulator's own register.

RegulatorLicence no.StatusLicensed entityDate
In our coverage
Financial Sector Conduct Authority
52108RegulatedJAROCEL PTY LTD08-04-2022

Peer regulatory & risk comparison

Side-by-side supervisory and risk benchmark comparing CXM against peer institutions in our institutions licensed across asia-pacific and the middle east dataset.

Full directory →
InstitutionPrimary regulatorsRegulated / totalRisk classificationSource scoreWarnings
CXM (this record)
FSCA
1 / 1Risk level not supplied6.10
FSCA
1 / 1Risk level not supplied5.00
FSCA
0 / 1Risk level not supplied4.50
FSCA
1 / 1Risk level not supplied4.00
FSCA
1 / 1Risk level not supplied4.00
FSCA
0 / 1Risk level not supplied3.60

CXM: institutional due diligence FAQ

Key supervisory, licensing, and counterparty verification questions generated from the dataset.

What is CXM's regulatory licence status and supervisory authorisation?

In our imported dataset, CXM (legal entity reference: CXM) holds 1 recorded licence entry, of which 1 carries a "regulated" status and 1 are marked regulated or registered: FSCA (Financial Sector Conduct Authority) — licence 52108, status: regulated. Institutional due diligence requires verifying that the exact legal entity on your counterparty agreement matches the licensed entity name and registration number on the official FSCA public register.

Which of CXM's jurisdictions and licences fall within this site's regulatory coverage?

This directory focuses on institutions licensed across asia-pacific and the middle east. 1 of CXM's 1 licence records fall directly within this jurisdictional mandate: FSCA (licence 52108, regulated, entity: JAROCEL PTY LTD). Always confirm whether client money segregation and statutory investor compensation schemes apply to the specific subsidiary onboarding your account.

What is CXM's institutional risk classification, enforcement exposure, and score profile?

CXM carries a "risk level not supplied" classification in the source dataset, alongside composite 5-dimension ratings out of 10 (overall: 6.1, risk & licensing: 6.0, brand: 6.3, market influence: 6.0, user reputation: 0.0). The record flags 0 regulatory warning or complaint counts. Because these figures reflect imported source fields rather than primary audit findings, compliance teams should review primary enforcement bulletins directly.

What operational due diligence steps apply to CXM's platforms, entity structure, and complaints?

Before allocating capital or executing trades with CXM (listed execution software: Headway Trading App), institutional and retail allocators should: (1) confirm the domain (hw.online) against regulator-approved domains to guard against clone firms; (2) verify whether any of the 0 recorded warning/complaint entries or 0 user comments involve withdrawal restrictions or scope violations; and (3) confirm the dispute-resolution ombudsman tied to FSCA.

Editorial briefings and compliance research from APAC Capital Brief relevant to CXM's supervisory scope.

All research →

APAC Regulatory & Capital Corridors

APAC Institutional Capital Corridors in 2026: Comparative Licensing, Capital Adequacy, and Cross-Border Settlement Across MAS, HKMA/SFC, JFSA, ASIC, and India GIFT City IFSCA

An institutional Asia-Pacific dispatch analyzing statutory licensing thresholds, base capital and liquid capital mandates, client money trust segregation, and digital-asset/derivatives execution corridors across Singapore (MAS), Hong Kong (SFC/HKMA), Japan (JFSA), Australia (ASIC), and India GIFT City (IFSCA).

Read briefing →

Market Insights

Nikkei 225 Rises to 61,248.59 for a Third Straight Gain as Chip Stocks Rally - BBN Times

Nikkei 225 Rises to 61,248.59 for a Third Straight Gain as Chip Stocks Rally - BBN Times: Nikkei 225 Rises to 61,248.59 for a Third Straight Gain as Chip Stocks Rally BBN Times

Read briefing →

Market Insights

Nikkei Flat, Supported by Bank, Pharma Stocks

Nikkei Flat, Supported by Bank, Pharma Stocks: Japan’s Nikkei Stock Average was flat at 60451.02 as gains in bank and pharmaceutical shares offset losses in technology and machinery stocks.

Read briefing →

TSE Governance & Equities

India Fully Accessible Route (FAR) Sovereign Bonds in Global Bond Indices: Benchmark Index Rebalancing & Passive Institutional AUM Impact (10.0% GBI-EM Maximum Index Weight Benchmark)

India Fully Accessible Route (FAR) Sovereign Bonds in Global Bond Indices (INDIA-FAR-BONDS) stands at 10.0% (GBI-EM Maximum Index Weight) (Source: Reserve Bank of India (RBI), 2026-10-20), governing TOPIX multi-phase flo

Read briefing →
CXM — Regulation, Licence Records & Risk Profile | APAC Capital Brief